The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the superfamily of nuclear hormone receptors. 2 It was first discovered in the early 1990s and since then has been identified as the master regulator of hepatic lipid metabolism. 3 Synthetic agonists of PPARα lower plasma triglycerides and increase plasma high-density lipoprotein (HDL) levels and are thus used clinically in the treatment of dyslipidemia. 4 The peroxisome proliferator-activated receptor alpha (PPARα) is a ligand activated transcription factor involved in the regulation of a variety of processes, ranging from inflammation and immunity to nutrient metabolism and energy homeostasis. PPARα serves as a molecular target for hypolipidemic drug fibrates. 1 The receptor has a central role in fatty acid oxidation, lipid and lipoprotein metabolism, inflammatory responses, and oxidative stress.
Peroxisome proliferator-activated receptors (PPARs) are activated by fatty acids and derivatives. PPARα mediates hypolipidemic action and PPARγ mediates the antidiabetic action of drugs. PPARα is highly expressed in liver, muscle, kidney, and heart, where it stimulates the β-oxidative degradation of fatty acids. 5 Activation of the PPAR is initiated by binding of an agonist, either an endogenous substance (e.g., fatty acids, eicosanoids, or oxidized phospholipids) or a drug to the ligand binding domain of the nuclear receptor forming heterodimers with retinoid X receptor (RXR), another nuclear receptor activated by its own ligand (purported to be 9 cis-retinoic acid).
The PPAR-RXR complex subsequently binds to DNA at sequence specific regions on target gene promoters, known as PPAR response elements (PPRE), thereby activating their expression. 6 PPARs need to form heterodimers with RXR upon ligand binding to regulate gene transcription. 7 The PPAR/RXR heterodimer binds the PPRE site in the 5' promoter regions of target genes. 8 
PPARα and lipid metabolism
Activation of PPARα leads to increased tissue-specific expression of key genes involved in fatty acid uptake and β oxidation. This includes acyl-Coenzyme A synthetase, an enzyme which plays a key role in esterification of fatty acids thereby preventing their efflux from cells, in the liver and kidney, and carnitine palmitoyltransferase type 1 (CPT-1), a pivotal enzyme involved in fatty acid catabolism within mitochondria in metabolically active tissue such as the heart, skeletal muscle and brown adipose tissue, which contains a PPRE in its promoter region. 9 The net effect of this is reduction in the availability of free fatty acids for synthesis and secretion of very-low-density lipoproteins (VLDL).
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PPARα on triglyceride and low-density lipoprotein (LDL)
Metabolism
Activation of PPARα decreases triglycerides (TG) by stimulating free fatty acid β oxidation, hepatic lipoprotein lipase expression, and expression of apolipoprotein V (apoV), and by inhibiting expression of apolipoprotein CIII (apoCIII). 11 In vitro studies imply repression of apoCIII expression via interaction with a PPRE in the Reverb-α promoter, given that mice deficient in this protein exhibit increased plasma concentrations of TG and apoCIII. 12 An increase in apoCIII content of VLDL particles causes an increase in small dense LDL particles. PPARα activation leads to a reduction in the levels of atherogenic dense LDL-cholesterol that has poor affinity to LDL receptor while increasing large buoyant LDL particles that have a high affinity for this receptor. 14 This inhibits cellular cholesteryl ester formation and limits accumulation of cholesteryl ester in vascular macrophages, preventing foam cell formation. 15 PPAR activation also regulates cholesterol mobilisation, leading to enhanced availability of plasma membrane cholesterol for cholesterol efflux, which together with regulation of ABCA1 and SR-BI expression, stimulate reverse cholesterol transport. 16 
PPARα on atherosclerosis
PPAR is expressed in inflammatory cells involved in the process of atherogenesis, such as monocytes, macrophages and lymphocytes implying a regulatory role in the early stages of atherosclerosis. PPAR activators inhibit cytokine-induced expression of vascular cell-adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), both playing a critical role in the recruitment of leukocytes and monocytes to the atherosclerotic lesion, by down-regulation at the transcriptional level, mediated in part by inhibition of the NF-B signalling pathway. 17 PPAR ligands also repress thrombin-induced expression of endothelin-1 (ET-1), by negatively interfering with the AP-1 signalling pathway.
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LDL receptor
The low-density lipoprotein (LDL) receptor (LDLR) is the primary pathway for removal of cholesterol from the circulation, and its activity is meticulously governed by intracellular cholesterol levels. 19 Goldstein and Brown (2009) evaluated the molecular mechanism of LDLR in familial hypercholesterolemia (FH), an autosomal dominant metabolic disorder in patients with plasma cholesterol levels ranging from 300 mg/dL to 1500 mg/dL. 20 Patients with FH are at increased risk of cardiovascular disease and high cholesterol levels often results in advanced atherosclerosis within a time span of 10 years. 21 The low-density lipoprotein (LDL) receptor mediates the specific uptake of LDL from circulation and its intracellular degradation and this process is known as LDL receptor pathway. LDL receptor gene expression is regulated by intracellular sterol content of liver. Mutations in LDLR, the gene encoding the LDL receptor, cause familial hypercholesterolaemia (FH), a dominantly inherited disease where accumulation of LDL in circulation increases the risk of coronary heart disease. Defects in other genes, including APOB, encoding the ligand for the LDL receptor, ARH, encoding a protein required for its internalisation and proprotein convertase subtilisin/kexin type 9 (PCSK9), encoding a protein that reduces LDL receptor protein levels, cause a similar disorder because the encoded proteins are involved in the LDL receptor pathway. FH can readily be treated with cholesterol-lowering drugs to reduce cardiovascular risk effectively, and identification of the causal genetic defect allows unequivocal and early diagnosis.
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The LDL-receptor pathway for uptake and degradation of LDL The LDL receptor specifically binds to apolipoprotein B in LDL particles present in the extracellular fluid. The receptor-ligand complex is then internalized by endocytosis. The complex is transported to late endosomal compartment, where the acidic environment causes dissociation of the receptor-ligand complex. The receptor is again recycled to the cell surface while the LDL particle is degraded in the lysosomal compartment. Accumulation of free cholesterol released by hydrolysis of cholesteryl esters inactivates sterol regulatory element binding protein (SREBP), a transcription factor that drives expression of genes for enzymes involved in cholesterol synthesis and the LDL receptor. Mutations in LDLR, APOB, LDLRAP1 or PCSK9 are known to result in familial hypercholesterolemia.
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METHODS
This study was done at Central Animal House, Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar. All studies were conducted in accordance with CPCSEA guidelines. 
Materials
Chemicals and reagents
Lutein (4-[18-(4-Hydroxy-2,6,6-trimethyl-1-cyclohexenyl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-2-en-1-ol) was purchased from MP Biomedicals India Private Limited, Mumbai, Maharashtra. Cholesterol pure was purchased from Himedia, India. Cholic acid sodium salt, Pure was purchased from Himedia, India. Trizol reagent was purchased from Invitrogen, Calif., U.S.A. PCR primers (forward and reverse), and PCR Master Mix was purchased from Promega, N.Y., U.S.A. All reagents used in this study were of analytical grade.
Preparation of drug
Lutein 50mg/ml. Atorvastatin powder were dissolved in dimethyl sulfoxide (DMSO) to make a solution of 10mg/ml.
Animals
Healthy adult male rats of Wistar strain weighing 150-200gms were used in the present study. They were purchased from the Central Animal House, Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar, Tamil Nadu, India. Animals were housed in polypropylene cages [28cm x 22cm x 14cm] bedded with husk in groups of six under controlled environmental conditions [Temp-23±2 0 C, Humidity 65-70% and 12 hrs light/dark cycles] at Central Animal House, Rajah Muthiah Medical College and Hospital, Annamalai University. Animals were fed with standard pellet diet VRK Nutritional Solutions, Baramati Agro Limited, Sangli, Maharashtra, India] and water ad libitum.
Induction of hypercholesterolemia
Hypercholesterolemia was induced in all groups except control group by feeding cholesterol diet (1% cholesterol, 0.5% sodium cholate, 1% coconut oil) in rat chow. 24 
Study design
The rats were divided into 6 groups of six each (n=6).
• Group I (n=6) = Control. • Group VI (n=6) = Lutein 100mg/kg p.o daily with high cholesterol diet. 25 The drug treatment was carried out every day morning using intra-gastric tube for a period of 16 weeks.
Tissue sampling
At the end of the study, the animals were sacrificed by cervical dislocation and the Liver from all the groups of rats were dissected out and We stored tissues in RNA Later (Ambion), extracted total RNA with Trizol (Invitrogen) and they were processed for PPARα and LDLR gene expression through Q-RT-PCR.
RNA extraction
A volume of 1 cm 3 rat liver tissue was homogenized, and 500μL of Trizol reagent (Invitrogen, Calif., U.S.A.) was used to extract RNA. RNA was precipitated by mixing with isopropyl alcohol. The RNA pellet was washed twice with 75% ethanol and dissolved in diethylpyrocarbonatetreated water to a final concentration of 2.5μg/μL. 
Gene
Forward primer Reverse primer
Quantitative -Reverse-transcription PCR Q (RT-PCR)
A mass of 2.5μg of total liver RNA from each rat liver tissue was used for the 1st-strand cDNA synthesis (Fermentas, Ontario, Canada). In short, total RNA was mixed with oligo (dT)18, Moloney Murine Leukemia Virus (M-MuLV) reverse transcriptase, dNTPs, and RNase inhibitor to a final reaction volume of 20μL. The reaction was carried out at 25•C for 10 min, followed by 50•C for 15 min, and was terminated at 85•C for 5 min. PCR was then performed using 1μg of the 1st-strand cDNAs, 50nM of the PCR primers (forward and reverse), and PCR Master Mix (Promega, N.Y., U.S.A.). The primer sets used are shown in Table. The expression levels of the gene transcripts of interest were related to those of an internal standard housekeeping gene (Beta actin [β-actin]) to correct differences in quantity and quality among different RNA samples. The PCR amplification protocol consisted of a 1-step denaturation for 3min at 94•C, followed by 35 cycles of 1-min denaturation at 94•C, 1-min annealing at 55•C, and 1-min extension at 72•C. The PCR products were run on 0.8% agarose gel and stained with (Ethidium bromide (EtBr). The light intensity of each band was measured by the freeware Image J (ver.1.42). The expression levels of various genes were expressed as the ratios of the measured intensity of the gene of interest to that of β -actin.
RESULTS
This study results show that PPARα mRNA expression in liver tissue in Lutein treated male wistar rats increase in a dose dependant manner. The expression of PPARα in rat liver tissue was significantly decreased in high cholesterol fed rats. Atorvastatin 5mg/kg body weight (group 3)
showed statistically significant difference in comparison with high cholesterol fed rats in expression of PPARα. This study results show that PPARα mRNA expression in liver tissue in Lutein treated male wistar rats increase in a dose dependant manner. The expression of PPARα in rat liver tissue was significantly decreased in high cholesterol fed rats. Atorvastatin 5mg/kg body weight (group 3) showed statistically significant difference in comparison with high cholesterol fed rats in expression of PPARα.
The LDLR expression in rat liver tissue in Lutein treated groups was significantly increased in a dose dependent manner. Atorvastatin 5mg/kg body weight showed significant increase in expression of LDLR in comparison with high cholesterol fed rats.
DISCUSSION
Peroxisome proliferator activated receptor α (PPARα) also known as NR1C1 (Nuclear receptor subfamily 1 group c member 1) is a nuclear receptor protein and is encoded by PPAR α gene. 26 It is a transcription factor and major regulator of lipid metabolism in liver. It activates ketogenesis in conditions of fasting. 27 Activation of PPARα leads to uptake, utilisation and catabolism of fatty acids. 28 PPARα is expressed highly in tissues involved in fatty acid oxidation in liver and brown adipose tissue in rodents. 29 PPAR expression ligand binding can be analysed with PCR (polymerase chain reaction). PCR is a biochemical technology in molecular biology. It is used to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence.
Primers are short DNA fragments containing sequences complementary to target region along with a DNA polymerase. PPARα expression and ligand binding was increased in a dose dependant manner for lutein. The highest interaction was seen in lutein 100mg/kg group (group VI) suggesting its possible mechanism of action. Although atorvastatin acts mainly through inhibition of HMG CoA reductase enzyme, studies have reported the upregulation of the expression of PPARα by Atorvastatin. 30 In this study reports also showed that Atorvastatin increased the expression of PPARα. 
CONCLUSION
This study proved that Lutein potentiates the expression of PPARα and LDLR gene in hypercholesterolemic male wistar rats compared to high cholesterol fed rats. In this preclinical study, the prophylactic effect of lutein in hyperlipidemia, was evaluated and compared with Atorvastatin. Its possible mechanism of action was found to be through the activation of PPARα and further extensive clinical studies are needed to prove this claim.
